OEMs and start-ups that seek to bring a biosensor device to the medical market must be strategic in their approach or risk delays and inflated development costs. The design phase is a critical juncture, as decisions made during this stage are often the difference between a commercially successful biosensor device and one destined for significant redesign — or one that might not be viable at all. Read on for Dave Liebl’s seven best practices for starting a design process that fosters commercial success for medical biosensors, as featured in Medical Design Briefs. https://lnkd.in/gUAvv2vB

December 5, 2022

David Liebl, Intricon’s chief technology and commercial officer

David Liebl, Intricon’s chief technology and commercial officer, was a featured expert on Medical Design Briefs magazine webcast: Developing the Ultimate Medical Sensor Technology. Biosensor devices monitor and detect changes in biological processes and convert them into a physical signal. Biosensors can be close to the body, on the body, or in the body.

As companies develop such monitoring devices that incorporate sensors, it is important for them to understand how to partner to effectively and cost-efficiently bring their devices to the medical market. On the webcast, Dave provided guidance on:

Intricon is part of a growing wearable biosensor ecosystem, providing unsurpassed expertise in miniaturized electronics for biosensor innovation through prototyping, testing, validation, product launches, and fulfillment. Intricon uses technical capabilities and regulatory acumen as a contract development manufacturer in the wearable biosensor industry for manufacturers of biosensors used in pulmonology, remote patient monitoring, audiology, orthopedics, endocrinology, and gastroenterology.

Since 1977, Intricon has been bringing bioelectronic devices to life. Over 45 years, it has grown and evolved processes and capabilities to create biosensors that are smaller, lighter, and more comfortable for patients. As a contract manufacturer exclusive to medical technology, the company partners with industry leading medical device companies from around the globe to build world-class products that make the lives of patients better.

The webcast can be viewed by visiting https://event.webcasts.com/starthere.jsp?ei=1579008&tp_key=2a980ad4bb

Dave Liebl Promoted to Intricon Chief Commercial and Technology Officer

Dave Liebl Intricon Chief Commercial and Technology Officer
Dave Liebl Intricon Chief Commercial and Technology Officer

Intricon has named Dave Liebl as its first Chief Commercial and Technology Officer (CCO/CTO).

“The new role is essential as we enhance our commercial growth strategy. Dave’s commercial experience makes him an ideal leader for Intricon’s next phase of growth and development,” said Scott Longval, president and chief executive officer of Intricon. “In Dave’s expanded role, he is responsible for accelerating our innovation roadmap and expanding our customer relationships.”

Dave’s career includes more than 25 years of business development, engineering, and product development experience at multiple high technology and medical technology companies. Prior to joining Intricon in August 2021 as vice president of research and development, Dave served as the president of Biomerics NLE’s West Operations. Prior to his role at Biomerics, he held several roles at Heraeus Medical Components/NeoMetrics, Inc., including EVP, product and business development, president and chief technology officer, and VP of development, spanning from 2005 to 2019. His career also includes director and vice president level positions at Pearson, Datacard Group, and MedAmicus, Inc. (now part of Integer Holdings).

“Intricon has a strong foundation of core competencies and technologies, which are well positioned to meet the needs of industry trends. Further, our global manufacturing footprint enables us to meet customer cost targets,” said Dave. “I’m looking forward to pursuing opportunities in high-growth markets by advancing our technology and commercial operations to meet and exceed our customers’ expectations.”